Haemopoietic cell transplantation in patients living with HIV

Lancet HIV. 2020 Sep;7(9):e652-e660. doi: 10.1016/S2352-3018(20)30117-X. Epub 2020 Aug 10.

Abstract

Haemopoietic cell transplantation is established as a standard treatment approach for people living with HIV who have haematological malignancies with poor prognosis. Studies with autologous and allogeneic haemopoietic cell transplantation suggest that HIV status does not adversely affect outcomes, provided that there is adequate infection prophylaxis. Attention to possible drug-drug interactions is important. Allogeneic haemopoietic cell transplantation substantially reduces the long-term HIV reservoir when complete donor chimerism is established. When transplants from CCR5Δ32 homozygous donors are used, HIV cure is possible.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antiretroviral Therapy, Highly Active
  • Disease Management
  • Disease Susceptibility
  • Genetic Predisposition to Disease
  • Graft vs Host Disease / etiology
  • HIV Infections / complications*
  • HIV Infections / drug therapy
  • HIV Infections / immunology
  • HIV Infections / virology
  • Hematologic Neoplasms / complications
  • Hematologic Neoplasms / therapy
  • Hematopoietic Stem Cell Transplantation* / adverse effects
  • Hematopoietic Stem Cell Transplantation* / methods
  • Homozygote
  • Humans
  • Mutation
  • Receptors, CCR5
  • Transplantation, Autologous
  • Transplantation, Homologous
  • Treatment Outcome

Substances

  • CCR5 protein, human
  • Receptors, CCR5